Eating Peanuts for Health

NCT ID: NCT01886326

Last Updated: 2013-06-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

196 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evidence is accumulating that peanut consumption confers health benefits, such as reduction of cardiovascular disease risk and possibly diabetes risk (Jenkins et al., 2008; Mattes et al., 2008). However, peanuts are a high fat, energy dense food and concerns about weight gain are widespread. Although research indicates that other characteristics of peanuts offset these properties, and that peanuts may be incorporated into diets without posing a threat to weight gain (Mattes et al., 2008), concern remains among policymakers, healthcare providers, and consumers. Furthermore, worry exists that eating salted peanuts may elevate blood pressure and that eating honey-roasted peanuts make elevate blood sugar. These fears create substantial obstacles to increased peanut consumption.

Recommendations to increase peanut consumption may be made, but if they are not followed, there will be no impact on health. Additional knowledge is needed on: (1) the acceptability of peanuts consumed on a chronic basis, (2) the chronic intake of moderate levels of peanuts and body weight, and 3) the effects of peanuts on blood pressure and blood sugar. The proposed research will examine the acceptability of long-term inclusion of a single form versus varied forms of peanuts in the diet. It is expected that responses will be varied among individuals with different personality characteristics (e.g., prefer sweet versus savory foods, hedonic versus non-hedonic eaters). A better understanding of how different segments of the population choose to include peanuts in their diet and how to optimize long-term consumption should provide insights for better marketing and improved health. Furthermore, it is anticipated that eating salty peanuts will not raise blood pressure and that eating honey-roasted peanuts will not raise blood sugar. Documenting this will add credibility to the evidence that peanuts do not cause weight gain, as well as reinforce recommendations to increase peanut consumption for their health benefits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Overweight Hyperlipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Consumption of 42 g of salted peanuts

Consumption of 42 grams of peanuts daily

Group Type EXPERIMENTAL

Consumption of 42 grams of peanuts daily

Intervention Type OTHER

Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Consumption of 42 g of unsalted peanuts

Consumption of 42 grams of peanuts daily

Group Type EXPERIMENTAL

Consumption of 42 grams of peanuts daily

Intervention Type OTHER

Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Consumption of 42 g of spicy peanuts

Consumption of 42 grams of peanuts daily

Group Type EXPERIMENTAL

Consumption of 42 grams of peanuts daily

Intervention Type OTHER

Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Consumption of 42 g of honey peanuts

Consumption of 42 grams of peanuts daily

Group Type EXPERIMENTAL

Consumption of 42 grams of peanuts daily

Intervention Type OTHER

Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Consumption of 42 g of 3 diff. varieties

Consumption of 42 grams of peanuts daily

Group Type EXPERIMENTAL

Consumption of 42 grams of peanuts daily

Intervention Type OTHER

Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Consumption of 42 g of var. of types

Consumption of 42 grams of peanuts daily

Group Type EXPERIMENTAL

Consumption of 42 grams of peanuts daily

Intervention Type OTHER

Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Consumption of 42 grams of peanuts daily

Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between 18 and 50 years of age
* Weight stable (\< 3 kg weight change within last 3 months)
* Constant habitual activity patterns (no deviation \> 1x/wk at 30 min/session within last 3 months)
* Constant habitual diet patterns within last 3 months
* Willingness to eat all test foods (peanuts daily for 12 weeks)
* No allergy to foods provided in the study (peanuts)
* Not a daily peanut or tree nut consumer
* Not planning to change use of medications known to influence appetite or metabolism
* Not diabetic or hypertensive
* No history of gastrointestinal pathology
* Non-smoker for one year or more

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United States Agency for International Development (USAID)

FED

Sponsor Role collaborator

Purdue University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Richard Mattes

Distinguished Prof. Foods and Nutrition

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard D Mattes, RD, MPH, PhD

Role: PRINCIPAL_INVESTIGATOR

Purdue University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Purdue University

West Lafayette, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Jones JB, Provost M, Keaver L, Breen C, Ludy MJ, Mattes RD. Effects of daily consumption of one or varied peanut flavors on acceptance and intake. Appetite. 2014 Nov;82:208-12. doi: 10.1016/j.appet.2014.07.023. Epub 2014 Jul 23.

Reference Type DERIVED
PMID: 25064672 (View on PubMed)

Jones JB, Provost M, Keaver L, Breen C, Ludy MJ, Mattes RD. A randomized trial on the effects of flavorings on the health benefits of daily peanut consumption. Am J Clin Nutr. 2014 Mar;99(3):490-6. doi: 10.3945/ajcn.113.069401. Epub 2013 Dec 18.

Reference Type DERIVED
PMID: 24351876 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0912008773

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.